1. Seasonality The CAD is bullish during the first week of December, while the USD exhibits bearish momentum. This combination suggests a bearish outlook for USDCAD based on seasonality. 2. COT Report The COT report for the CAD suggests a sell. On the other hand, the COT report for the USD suggests a buy, indicating increasing strength for the USD. This could provide upward pressure on USDCAD. 3. Fundamental Analysis LEI The USDCAD LEI is increasing, which signals potential strength for the USD and could favor upward movement in USDCAD. Endogenous Factors The endogenous factors for the USD are increasing, suggesting bullish momentum for the USD, while the CAD's endogenous factors show weakness, further supporting a potential rise in USDCAD. Exogenous Factors Exogenous indicators for USDCAD show a decreasing trend, suggesting some resistance to further bullish momentum, which could limit the upside potential of USDCAD. 4. Technical Analysis USDCAD is forming an ABCD pattern, with the C point retracement at the 0.79 Fibonacci level. Bias The combined analysis suggests a bullish bias for USDCAD Trade Plan Entry: 1.40481 SL: 1.39756 TP: 1.41206
Without exaggeration, we have reached the destination of this upward rally on the Dow Jones index. A correction of about 4000 points is expected before continuing the trend.
Hey guys, I see two potential moves during Asia/London today. Take advantage and enjoy 40-50 pips in any directions. BUY: Taps into FVG 2640.71 body candle close above it buy towards 2654 SELL: Taps into FVG 2639.12 and body candle closes below sell towards 2626 and below PEPPERSTONE:XAUUSD Trade smart, Trade safe
This baby is gonna rocketship as we broke critical areas toward 12$ and 26$ next. With a cup target of around 8.5$. Structurally this coin on the 4H is very similar to ADA but hasnt seen that explosive breakout yet. The chart is a literal 1:1 replica of ADA before the breakout. It's coming...
Price of #sol is sitting in a very strong support zone at $222. As long as price stays above this zone, a retest back to it's previous weak high which it's created at $264 level is certain and we could see #sol break through all the way up to $300..
Our last post for reference: https://www.tradingview.com/chart/WIFUSDT/PnjNG9YS-WIF-Breakout-in-Progress/ One of the thing we were watching for was if we would get a retest of the triangle. This would flip old resistance into new support. Today we get that retest and have so far closed 2 8H candles directly above the trendline showing buying strength in this range. As long as we do not see an 8H candle close back within the triangle, this should be the start of the breakout.
Strategy Episodic pivot 2 Dec Entry Grading B 7points - But increased position size to 2R because it is episodic pivot Intel Announces Retirement of CEO Pat Gelsinger This trade is episodic and driven by attention. Purchased a $400 position; D1 shows a gap clearly above the 100SMA. The stop loss is set 8.74% below the recent low. With the average ADR% at 3.74%, the stop loss provides a safe buffer for price development. If this mirrors the Starbucks trend (+20%), it could jump on the announcement of a new CEO or positive development. Grading B 7points Idea based on recent hype +3 Greater force - There is alignment with SPX +2 Technicals - D1 and H1 recently above 100SMA
Mana seems promising but I will take profits in the above blue line zone. Both Daily and Weekly Candle shows resistance. And the hanging sword of weekly stoch RSI still there. Ofcourse its more wild run above but be careful. Again not a financial advise. I try to learn everytime.
Price of #sol is found trading in a very strong support zone, As long as price stays above this zone, a retest back to it's previous weak high which it's created at $264 level is certain and we could see #sol break through all the way up to $300..
ANVS is a clinical-stage biotech company, working on a drug for Alzheimer's Disease (AD). I believe in their approach toward AD, compared to all the other companies that are trying to remove amyloid plaques, which doesn't help fight AD. Check out annovisbio.com/our-science for more of the scientific stuff. Suffice to say, I believe in the science behind these guys so I think they are safe from going to 0 in the immediate future. That's about as good as you can hope, from a clinical-stage biotech! For the immediate future, and I'm just talking this month December 2024, I think it could have a strong return this month. Watch the 34-period ema in 65-minute chart (you can use 60-minute chart if you do not have a paid plan, as an approximation). Current price $7.28, at market close on first day of December (+8.5% today).